NeuroSentry was selected as one of 12 companies for the Fall 2025 cohort of FAST California, the flagship startup advisory program of California Life Sciences (CLS).
Through the program, NeuroSentry worked with a curated team of experienced life sciences advisors to strengthen our commercialization strategy, refine our business model and go-to-market approach, and prepare for the next stages of company growth.
The program culminated in the California Life Sciences Innovation Showcase, where NeuroSentry presented its EEG-based stroke detection platform to an audience of investors, industry leaders, and potential collaboration partners.
Participation in FAST California was an important early milestone in translating NeuroSentry's clinical and technical foundation into a focused strategy for bringing continuous, real-time stroke detection to clinical care.
More Details: https://www.califesciences.org/fast-california/2025-fall/
